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Transcription factor Pit-1 affects transcriptional timing in the dual-
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Gene transcription occurs in short bursts interspersed with silent periods, and these kinetics can be 
altered by promoter structure. The effect of alternate promoter architecture on transcription bursting is 
not known. We studied the human prolactin (hPRL) gene that contains two promoters, a pituitary-
specific promoter that requires the transcription factor Pit-1, and displays dramatic transcriptional 
bursting activity, and an alternate upstream promoter that is active in non-pituitary tissues. We studied 
large hPRL genomic fragments with luciferase reporters, and used bacterial artificial chromosome 
(BAC) recombineering to manipulate critical promoter regions. Stochastic switch mathematical 
modelling of single-cell time-lapse luminescence image data revealed that the Pit-1-dependent 
promoter showed longer, higher-amplitude transcriptional bursts. Knockdown studies confirmed that 
the presence of Pit-1 stabilised and prolonged periods of active transcription. Pit-1 therefore plays an 
active role in establishing the timing of transcription cycles, in addition to its cell-specific functions.  
 
Key words 




















Prolactin is a multifunctional mammalian hormone with a major role in lactation as well as other 
biological functions, including reproduction, immunomodulation and behaviour [1, 2]. This 
polypeptide hormone mainly originates in the lactotroph cells of the anterior pituitary gland, but is 
also expressed at extra-pituitary sites, such as brain, decidualised endometrium, myometrium and 
circulating lymphocytes, and hence requires tissue-specific transcriptional control mechanisms to 
regulate its functional versatility [1-3].  
 
The human PRL (hPRL) gene is located on the short arm of chromosome 6 and consists of five 
coding exons within a region of 10 kb. The gene has two distinct, alternative promoter elements that 
are 5.8 kb apart and show selective and tissue-specific activation [2, 4]. The proximal promoter is 
located immediately upstream of exon 1b and regulates hPRL transcription in the pituitary gland. This 
is often referred to as the pituitary-specific promoter and contains multiple binding sites for the 
pituitary-specific transcription factor Pit-1 [5, 6]. In lymphocytes and human endometrial cells, hPRL 
expression has been shown to be driven by an alternative promoter, upstream of the pituitary 
transcriptional start site [7]. This evolved from a long terminal repeat-like transposon, resulting in 
transcription of the additional exon 1a, giving rise to mRNA that is 150 bp longer than the pituitary 
mRNA [2, 8]. The different sized transcripts do not give rise to different protein isoforms, but are 
believed to contribute an additional level of regulation of PRL transcription in different cellular and 
functional contexts (pituitary versus extra-pituitary) by influencing the stability or translational 
efficiency of alternatively transcribed messages [2, 8]. Expression of the longer alternative promoter 
transcript has classically been viewed as a product of extra-pituitary sites, and considered to be Pit-1 
independent [4, 9, 10].  
 
Pit-1 (also known as POU1F1) is a member of the POU family of transcription factors that are 
characterised by the presence of a bipartite DNA binding domain, known as the POU domain [11]. It 
is essential for the differentiation of lactotroph, somatotroph and thyrotroph cells; Snell and Jackson 
dwarf mouse models carry mutations in the Pit-1 gene and show no development of these pituitary 
cell types [6], and Pit-1 mutations commonly result in hypopituitarism [12]. Additionally, Pit-1 
binding has been shown to play a crucial role in both basal and hormonally induced activity of the 
hPRL promoter [13-15].  
 
The hPRL genomic locus has many conserved regions far upstream of the transcriptional start site. 
Outside of the genomic locus, the PRL gene is surrounded by over 1Mb of non-coding DNA, a gene 
desert which could have a functional impact on hPRL regulation [16]. It has therefore been important 

















BAC based reporter systems permit the inclusion of far-distant regulatory elements and can prove 
particularly beneficial in analysing function of promoters that comprise a complex array of cis-acting 
regulatory elements [7, 17, 18]. We previously generated a BAC reporter construct which spanned 
163Kb of the hPRL genomic locus including 115kb upstream and 38kb down-stream of the PRL gene 
and expressed firefly luciferase (Luc) under the control of the entire hPRL gene  (referred to as hPRL 
WT BAC) [18].  
 
In our earlier work, single cell imaging of the hPRL WT BAC in pituitary cell lines and tissues,  
showed that the hPRL gene displays dramatic pulses in transcriptional activity [19, 20].  This activity 
has been observed for many other genes, including the hGH (human growth hormone) gene  [21], and 
appears to be a general phenomenon that is intrinsic to gene regulation [21-27]. The characteristics of 
these transcriptional pulses may be susceptible to modulation, as part of normal physiological control, 
and this might be expected to impact on overall levels of gene expression. In the present study, to 
study the role of Pit-1, we have compared the hPRL WT BAC with a construct in which the entire 5kb 
pituitary promoter was deleted, leaving intact exon 1a and the upstream promoter (referred to as hPRL 
PitProKO BAC). We compared the transcriptional behaviour of the two constructs when they were 
stably transfected into GH3 pituitary cell lines and found that the alternate promoters directed distinct 
patterns of transcriptional bursting in single cells. We examined the role of Pit-1 binding sites and the 
effect of modulation of Pit-1 levels in pituitary cells, and found that rather than just being necessary 
for transcription, the binding of Pit-1 regulates the timing of hPRL transcription. These data suggest a 
new and unsuspected function of this well studied transcription factor in regulating the dynamics of 
pituitary-specific gene expression in an important tissue model for the control of endocrine function. 
Material and Methods 
 
Generation of hPRL pituitary promoter knock-out BAC (hPRL PitProKO BAC) 
The generation of hPRL WT BAC with Luc reporter has been described previously [18]. The hPRL 
WT BAC spans 163 kb of the human PRL genomic locus including 115 kb upstream and 38 kb 
downstream of the PRL gene (10kb) and expresses the luciferase reporter gene under the control of 
both the hPRL proximal and alternative promoters. In order to study specific prolactin gene activation 
via the alternative promoter, we sought to remove pituitary-specific promoter elements from the hPRL 
WT BAC by the targeting strategy based on the seamless recombineering technology [28]. Briefly, 
the ~5kb hPRL proximal promoter was first replaced with the GalK (E.coli galactokinase k gene) 
coding sequence. A positive recombinant selected on galactose containing minimal media, was 
subjected to a second round of recombination to remove the inserted GalK sequence and replace with 
the short (256bp) immediate hPRL promoter sequence necessary for transcription initiation which 
also contains the alternative RNA splice acceptor site at position -246 relative to Luc translation start 

















site directed mutagenesis below) prior to recombination to remove remnants of pituitary-specific 
regulatory elements. Positive recombinants were identified through glycerol/deoxygalactose screening 
and BAC size and integrity confirmed by pulse field gel electrophoresis (PFGE). Mutations in Pit-1 
binding sites were confirmed by sequencing. The following two primer sets (italics denote homology 
arm sequence) were used for primary and secondary recombination respectively;  
 
Chimeric PrlGalK-F GAAATCGTAACTGATAAAAAATCAGCTT 
GACTATATCTATTGATTCTCAGACCTGTTGACAATTAATCATCGGCATAGTATATCG. 
Chimeric Prl GalK-R 
GTCTCACGGTTTTCTCTTTCCCAGATATTGGCTTTATAAACCTTTGATATCTTCTCAGCAC 
TGTCCTGCTCCTTGTGA.  
Chimeric Pit1-3-F GAAATCGTAACTGATAAAAAATCAGCTTGACTATAT 
CTATTGATTCTCAGACTCACCTTCATCTTTCTCTC.  




The hPRL 5kb Luc plasmid used for generation of the 256bp intermediate hPRL promoter sequence 
has been described previously [29]. Site mutations were induced in the three Pit-1 binding sites 
contained within the 256bp region [13, 30] present in the proximal pituitary promoter (-250/+1) using 
the QuikChange™ Site-Directed Mutagenesis Kit (Stratagene, Cambridge, UK) following the 
manufacturers guidelines. Oligonucleotides used for the mutation of Pit-1 sites are shown below.    
Site 1, 5′-gcctgattcattCGCtAcCtgaagatatcaag-3′; site 2, 5′-tcttcctgaatatgGatCCgaaataaaatacc-3′; site 
3, 5′-cttttggcctaatCCatGGaaatccttcctag-3′. Capital letters represent mutated bases which resulted in 
the introduction of unique restriction sites as Kpn1, BamH1 and Nco1 respectively. These restriction 
sites were subsequently used for screening the mutated clones.  The 256bp region with mutated Pit-1 
binding sites was amplified with BAC homology arms appended to primers and recombineered into 
the hPRL BAC Luc construct with deleted proximal promoter. 
 
Cell culture and generation of stably transfected BAC cell lines 
Pituitary GH3 cells were maintained in phenol red-free DMEM with pyruvate/glutamine and 10% 
fetal bovine serum (FBS). Jurkat cells were cultured in RPMI (Life Technologies Inc., Gaithersburg, 
MD) supplemented with glutamine and 10% FCS. Serum starving conditions were in media 
containing 0.25% BSA in place of FBS. 
 
For stable transfection of cell lines, BAC DNA (hPRL WT BAC or PitProKO BAC) was prepared by 



















GH3 cells in a 10cm dish or 2 × 10
6  
Jurkat cells in 25cm
2
 flask using ExGen500 transfection reagent. 
Media was changed 48h post transfection and supplemented with 500g/ml G418. Media + antibiotic 
were refreshed every 3-4 days. Colonies formed 2-3 weeks after culturing in selective media were re-
cloned into individual wells of a 48 well plate. The stable transfectant clones which were found 
positive for Luc expression were sequentially scaled up to large culture vessels as necessary. 
Endpoint luminometry assays 
GH3 cells (1×10
6
) were washed once with PBS then lysed using 200l of lysis buffer (25mM 
Tris/PO4, 10 mM MgCl2, 5 mm EDTA, 15% glycerol, 0.1% Triton X-100, and 0.1 mg/ml BSA). Cell 
lysis was aided by agitation at room temperature for 15 minutes, ATP added to a final concentration 
of 1mM and luciferase activity of samples measured using a FLUOstar Omega (BMG Labtech). Each 
experiment was performed in duplicate in three independent studies.  
 
Live-cell luminometry assays 
Pituitary GH3 cells (1.5×10
4 
per well) were seeded into 96-well microplates (white opaque, 
PerkinElmer) in serum-free media containing 1mM luciferin (Biosynth). After 24 hours (h) cells were 
stimulated as indicated and microplates sealed with Breathe-Easy sealing film (Sigma). Luciferase 
activity from each well was measured using FLUOstar Omega (BMG Labtech) over a period of 24h 
while maintaining the cells at 37C in the presence of 5% CO2. Photon counts from each well were 
integrated over 5 seconds (s) after every 15 minutes (min). Results are shown as mean fold induction 
relative to an untreated control and represent triplicates of three independent experiments. 
 
ChIP assay 
GH3 cells containing hPRL WT BAC or hPRL PitProKO  BAC (3.5× 10
6
) were seeded in 10cm 
dishes and left for 48h. ChIP assay was performed as described previously [31] based on the protocol 
by Upstate Biotechnology. Immunoprecipitation was carried out using 5g of either anti-Pit-1(X-7; 
Santa Cruz [32]) or a non-specific IgG (Santa Cruz). DNA was purified and amplified by PCR with 
the following primers: Pit-1 3 forward 5’-AAATCCTTCCTAGAATGTTC-3′ and Pit1 1 Reverse 5
′- AATCAGGCATTCGTTTC-3′ amplifying 145 bp of DNA.; rat GAPDH forward 5′- 
GAAATGGGCTTAGGGGTGAT-3′   and reverse 5′- TTAAGGATGGCCTTGGACTG-3′. 
 
RT-PCR 
Total mRNA was extracted from GH3 and Jurkat cells stably transfected with PRL-Luc BAC or 5kb 
Null BAC using an RNeasy kit (Qiagen, Valencia, CA). Genomic DNA was removed using gDNA 
eliminating columns provided with the kit. First strand cDNA was synthesized using random octamers 

















derived Luciferase mRNA was performed using forward primer 98 [7] in PRL exon- 1a and reverse 
primer 11 [18] in the Luciferase gene. 
 
Real time luminescence imaging 
GH3 BAC transfectant cells and collagenase dispersed primary pituitary cells were cultured in 35mm 
glass coverslip-based dishes (Greiner Bio-One, UK) in the presence of 10% FBS. Luciferin (1mM) 
was added at least 10h before the start of the imaging. Cells were transferred to a Zeiss Axiovert 200 
microscope in a dark room, equipped with an incubator maintained at 37C, 5% CO
2
 in humid 
atmosphere. A bright-field image was taken before and after the luminescence imaging to track the 
localisation of cells. Luminescence images were obtained using a Fluar 10x, 0.75 NA objective. 
Images were captured using a photon-counting charge coupled device camera (Orca II ER, 
Hamamatsu Photonics, UK). Sequential images, each integrated over 10 min, were acquired using 
Kinetic Imaging software AQM6 (Andor, Belfast, UK). The same software was used for the analysis 
of the imaging data. Regions of interest were drawn around each single cell, and total photon counts 
for individual cell areas were obtained from each image. Mean luminescence intensity data were 
collected after the average instrument dark count (corrected for number of pixels being used) was 
subtracted from the luminescence signal. Each imaging experiment was performed at least 3 times, 
with a representative experiment presented in figures.  
 
Real-time luminescence imaging of primary bone marrow cells from hPRL-Luc transgenic rats  
The generation of hPRL-Luciferase rats has been described previously [18]. Bone marrow (BM) cells 
were harvested from male hPRL-Luc rats, and erythrocytes were removed with ammonium chloride 
lysis solution. BM cells were cultured in RPMI 1640 containing 10% (V/V) FBS in 35mm glass 
coverslip based dishes (Greiner Bio-One, UK) and left to adhere. Luciferin (1mM (Biosynth)) was 
added at least 6h before the start of the experiment. Cells were imaged with a Zeiss Axiovert 200, 
equipped with an XL incubator (maintained at 37C in a 5% CO2 in humidified conditions) in a dark 
room. Luminescence images were collected using a Fluar 10×, 0.5-NA objective (Zeiss), and captured 
using a photon-counting charge coupled device camera (Orca II ER; Hamamatsu Photonics). 
Sequential images were taken with a 30 minute integration period, then analysed using Kinetic 
imaging software AQM6 (Andor). Lipopolysaccharide (LPS) was added directly to the dish (0.05% 
final concentration. Imaging experiments were performed 3 times, with a representative experiment 
shown in Figure 1b.  
 
Pit-1 siRNA knockdown 
For siRNA transfections 1.5x10
5
 hPRL WT GH3 cells were seeded into 12 well plates with 15pmol of 
Pit-1 Stealth RNAi
TM 
(ThermoFisher Assay ID HSS108266) in the presence of Lipofectamine 

















also transfected in the same manner with Stealth RNAi
TM
 siRNA negative control, medium GC 
duplex to control for sequence independent effects. Seventy two hours after transfection cells were 
used for live cell luminescence imaging experiments or lysed to assess the efficiency of Pit-1 
knockdown. 
 
Cell lysis and immunoblot analysis 
After transfection with either Pit-1 siRNA, siRNA negative control or lipofectamine RNAimax 
reagent only, hPRL-WT GH3 cells were lysed with Laemlli sample buffer (2% SDS, 60mM Tris-Cl 
(pH 6.8) 0.02% bromophenol blue, 0.1M DTT). Proteins were resolved by SDS-PAGE, transferred to 
nitrocellulose and blocked in 5% non-fat milk. Blots were incubated in primary antibodies over night 
at 4
o
C (Abcam), washed and then incubated with horse radish peroxidase conjugated secondary 
antibodies and developed using enhanced chemiluminescence. Efficiency of Pit-1 knockdown was 
assessed in at least 3 experiments. 
 
Stochastic switch model analysis 
To quantify the duration of transcriptional phases raw single-cell luminescence data from 3 
independent experiments for each imaging condition (hPRL WT, PitProKO, hPRL WT Pit-1 
knockdown and hPRL WT scrambled siRNA experimental conditions) was analysed using a 
previously developed stochastic switch model (SSM) [33]. This model utilized a reversible jump 
Markov chain Monte Carlo algorithm using back-calculated transcription rates from an observed 
luciferase signal to identify transcriptional switches, using known luciferase protein and mRNA 
degradation rates previously reported in GH3 cell lines, as used in the present study [33]. This 




Contrasting cycles of hPRL transcription directed by the alternative and proximal promoters 
Pulsatile cycles of prolactin transcription have previously been shown in single cells from pituitary 
cell lines and in primary pituitary cells [17-20, 29, 34-37]. hPRL promoter directed reporter gene 
expression has also been observed in primary cultures of bone marrow myeloid cells (taken from 
transgenic rats expressing luciferase under the control of the hPRL WT BAC), where it is driven by 
the alternative promoter. This expression is significantly enhanced through cytokine stimulation, such 
as LPS treatment [35]. 
 
The first aim was to compare the dynamic behaviour of the wild-type hPRL promoter (hPRL WT 
BAC) in pituitary and non-pituitary cells, using primary pituitary cells and bone marrow myeloid cells 

















were observed with bursting characteristics in both systems (Figure 1, c and d). However, comparison 
of the observed transcription cycles suggested a shortening of the ‘on period’ in extra-pituitary cells, 
in which cycles of transcription are driven by the alternative promoter (Figure 1, e and f).  
 
Generation of the proximal-promoter knock-out hPRL BAC Luc (hPRL PitProKO BAC) construct 
In order to evaluate the influence of promoter architecture on transcriptional bursting the hPRL WT 
BAC was modified to delete the entire 5kb proximal pituitary promoter, leaving the upstream exon 1a 
and the alternative promoter intact (Figure 2a). This provided a construct in which luciferase 
expression was directed from the upstream alternative hPRL promoter, enabling direct comparison 
with the hPRL WT construct. The hPRL proximal promoter contains an alternative splice acceptor 
site (ASAS) at position -246 relative to its transcription start site, which is important for the function 
of the alternative promoter [18] (for diagrammatic analysis of the region and constructs see Figure 3). 
In addition, this region contains three Pit-1 binding sites, which could have the potential to drive 
expression from the pituitary promoter. We therefore performed site-directed mutagenesis to remove 
the three Pit-1 binding sites in the hPRL Luc 5kb plasmid (described previously [29], Figure 2b). 
After mutation, a 256bp DNA sequence containing the ASAS and mutated Pit-1 binding sites was 
amplified from the hPRL Luc 5kb plasmid and inserted into the hPRL Luc BAC with the 5kb pituitary 
promoter region deleted (Figure 2c). Chromatin immunoprecipitation (ChIP) confirmed absence of 
Pit-1 binding to the mutated construct (Figure 2d). The resulting hPRL BAC, termed PitProKO BAC, 
expresses luciferase under the control of the alternative promoter, and contains the ASAS and mutated 
Pit-1 sites. The remaining putative Pit-1 binding sites in the alternative promoter have previously been 
found to be non-functional [7], and were therefore not removed or mutated.  
 
The hPRL alternative promoter is active in GH3 pituitary cells independently of Pit-1 
The hPRL alternative promoter is often referred to as the extra-pituitary promoter, based on the notion 
that its activity is confined to sites outside of the pituitary. Here, to assess the contribution the 
alternative promoter plays in the transcriptional regulation of the hPRL gene in the pituitary, we 
generated rat pituitary GH3 stable cell lines expressing hPRL WT BAC-Luc or hPRL PitProKO 
BAC-Luc. Incorporation of the entire BAC without truncation into the cell lines was confirmed 
following genomic DNA extraction, with PCR using primer sets spanning the entire BAC construct, 
including the deleted 5kb region (Supplemental, Figure S1 [38]). The luciferase expression levels of 
three WT and three PitProKO clonal GH3 cell lines were compared. All cell lines displayed high and 
fluctuating levels of reporter gene activity (Figure 4a-e). However, WT clonal lines showed markedly 
higher luciferase activity compared with PitProKO clones (as seen in Figure 4a-b, with quantitative 
luminometry in Figure 4e). These data confirm that the alternative promoter is active in pituitary cells, 


















To confirm bona fide alternative promoter activity, RT-PCR was performed using GH3 hPRL WT 
cells and a primer set to amplify from exon1a and a portion of the luciferase gene. A single 423bp 
product was detected that corresponded to the splicing of exon1a into exon 1b, thus bypassing the 
pituitary 5´UTR sequence which contains Pit-1 binding sites (Supplemental Figure 1b [38]). A single 
product (670bp) was also detected in the non-pituitary lymphoblastoid Jurkat cell line expressing the 
hPRL WT construct. This was 246bp longer than its pituitary counterpart and corresponded to a 
splicing of exon 1a to a position -246bp upstream of transcriptional start site. These results together 
show that luciferase expression observed from PitProKO cells is representative of hPRL alternative 
promoter activity, and that both proximal and alternative promoters contribute towards hPRL directed 
luciferase activity in GH3 pituitary cells.  
 
Functional activation of the alternative promoter in GH3 PitProKO cells was confirmed by measuring 
the transcriptional response to appropriate stimuli. Induction was markedly greater in hPRL-WT cells 
where both promoters were present (Supplemental Figure S2a [38]). The PitProKO promoter was 
non-responsive to both estradiol (E2) and tumour necrosis alpha (TNF) treatment (Supplemental 
Figure S2b [38]), supporting our previous studies demonstrating that the hPRL transcriptional 
response to these stimuli is mediated by an estrogen response element (ERE) in the proximal promoter 
(-1189 bp from the transcription start site), which is not present in the PitProKO construct [17, 39].  
 
The hPRL alternative promoter displays bursting gene transcription 
We have previously shown the pulsatile nature of hPRL transcription in pituitary cells using both 5kb 
and BAC constructs in pituitary cell lines and in normal pituitary tissue in transgenic rats (17, 20, 25, 
27-32). The recombinant BAC constructs allowed us to test whether this bursting transcriptional 
behaviour was specific to activity directed by the proximal promoter and whether Pit-1 binding 
elements were required. Real-time luminescence imaging was conducted over 20h periods in living 
cells to directly compare the dynamics of luciferase expression from single unstimulated hPRL WT 
and PitProKO cell lines (Figure 4a-d). Cyclical patterns of transcriptional activity were observed in 
both cell lines, with lower amplitude in the PitProKO cells (normalised data shown in Figure 4c and 
d). The amplitude difference was comparable to the difference in luciferase activity observed between 
hPRL WT and PitProKO clonal cell lines seen in luciferase assays (Figure 4e). In addition to a 
reduction in amplitude, analysis of single cell traces also revealed that the active ‘on’ periods of gene 
transcription appeared significantly shorter in PitProKO cells than in WT cells, in other words that the 
pulses seemed to be shorter and sharper than in the WT cells (Figure 4c and d insets). To quantify the 
differences in transcription timing between the two promoters, single-cell luminescence data was 
analysed using a previously described stochastic switch model (33). This modelling analysis 
confirmed a significant reduction in the ‘on’ time of the PitProKO promoter compared to WT cells 

















These data show that the hPRL alternative and proximal promoters both generate cyclical patterns of 
transcription, but that transcription in the absence of Pit-1 binding occurs at a reduced rate, with 
significantly shorter periods of active transcription in any given cycle.  
 
Binding of the pituitary-specific transcription factor Pit-1 to cis-acting regulatory elements plays a 
key role in prolonging the duration of ‘on periods’ of active gene transcription  
One major factor that could explain these differences in transcription timing was the presence or 
absence of Pit-1 binding to the different hPRL promoters, in different cell contexts. We hypothesised 
that rather than simply being required for pituitary hPRL gene expression, Pit-1 might also play a role 
in the timing of transcription and contribute to the stabilisation of efficient and productive 
transcription cycles. To test this possibility, siRNA was used to knock down Pit-1 expression in both 
cell lines, comparing the behaviour of the WT and PitProKO constructs (Figure 5). 
 
Knockdown of Pit-1 reduced transcriptional activity of the WT BAC construct, as seen in 
luminometry assays (Figure 5e), where Pit-1 expression was successfully reduced by greater than 
95% (Figure 5e inset). Quantitative analysis of single-cell transcriptional data by SSM confirmed that 
knockdown of Pit-1 resulted in a significant shortening of the on-period of transcription (Figure 5f), 
consistent with the findings from the BAC mutagenesis studies. The PitProKO BAC contains mutated 
Pit-1 binding sites; therefore knockdown of Pit-1 in these cells should have no effect on the timing of 
reporter gene expression. SSM analysis of single-cell imaging data showed no difference in the on-
periods of active transcription between PitProKO cells and in PitProKO cells in which Pit-1 
expression was successfully knocked down  (Supplemental Figure 3 [38]). 
 
Asymmetry between activation and deactivation during a transcriptional pulse  
In previous work [21] on the transcription of human growth hormone we identified an asymmetry in 
the number and size of rate-increasing and rate-decreasing switches, resulting in a predominance of an 
all-or-nothing activation step, followed by a multi-step graded reduction. We therefore investigated if 
there was such an asymmetry in the current system. To do this, each dataset (WT, PitProKO, WT-Pit-
1 knockdown and WT scrambled siRNA) was processed by the SSM, and to each switch in the 
transcription rate we associated a score S which is the ratio of the change in the rate to the highest of 
the rates before and after the switch. Thus, a switch with S close to 1 is more binary (complete) while 
one with a smaller S is partial. We found that for each construct and condition considered, the 
distributions of S for up and down switches were significantly different with the asymmetry clearly 
present. The down switches had substantially more partial events than the up switches which were 
dominated by complete switches (Figure 6). The distributions found for the PitProKO cells 
substantially differed from the other constructs. For both the up and down switches, there was a 

















when just the alternative promoter was available. This may be partly explained by the fact that the 
switches are smaller in magnitude. On the other hand, the distributions for the hPRL WT cells and 
those with the Pit-1 knockdown were very similar as can be seen from the cumulative distribution 
functions in Figure 6 m and n. This suggests that the proximal pituitary promoter is responsible for the 
more graded response seen in the WT, but that this response is not due to interaction of Pit-1 with the 
promoter. We hypothesise that the graded response is associated with extra transcriptional availability 
modulated by the proximal pituitary promoter, and that Pit-1 binding facilitates higher transcription 




Heterogeneity in gene expression within a cell population has been observed in numerous single-cell 
imaging studies where it has been shown in a diverse range of organisms that individual genes can be 
transcribed in short bursts of variable duration and frequency [19, 22-26, 37, 40]. Evidence supports 
several molecular mechanisms that together control and modulate transcriptional bursting, including 
nucleosome occupancy [41], chromatin modifications [19, 23, 42], transcription factor availability 
[23, 26, 42, 43] and promoter structure [23] (reviewed in [44]. We have used pituitary cells as a model 
system and studied the transcriptional bursting from two alternative promoters in the hPRL gene, in 
the presence or absence of the pituitary-specific transcription factor Pit-1. Using live-cell imaging of 
stably transfected cells, we identified the role of prolactin promoter elements in the determination of 
the transcriptional timing characteristics in single pituitary cells. We find kinetically distinct 
transcriptional bursting behaviour of the two alternative promoters within the prolactin gene, and that 
binding of Pit-1 to prolactin promoter elements prolongs the duration of ‘on-periods’ of active gene 
transcription. 
 
We previously generated a BAC reporter construct (hPRL WT) spanning 163 Kb of the human PRL 
genomic locus and engineered it to insert the luciferase reporter gene at the start of the hPRL exon 1b, 
thus preventing expression of the hPRL coding sequence [18]. We have studied the behaviour of this 
hPRL WT BAC reporter construct using in vivo and in vitro models [18, 20, 34, 35]. Whole body in 
vivo imaging of hPRL-luc BAC-transgenic rats using this construct revealed striking evidence of 
alternative promoter activation after immune challenge, demonstrating that this construct can display 
transcriptional control by both the exon 1b promoter and the alternative upstream exon 1a promoter 
[20, 35]. In order to determine the relative contributions of the two alternative promoter regions, in the 
present study we engineered the hPRL-luc BAC (referred to as the WT construct) by deleting the 
entire 5 kbp region of proximal promoter and inserting a 256 bp DNA fragment which contained 
alternative splice acceptor site and mutated non-functional Pit-1 binding sites (hPRL PitProKO BAC). 

















and hPRL gene exons and introns, together with 115kb upstream and 38 kb downstream flanking 
regions, but no functional Pit-1 responsive elements. The initial assumption in this work was that the 
two promoters in the hPRL gene locus would display clear differential cell-type-specific activation, 
namely that the exon 1b promoter with its multiple Pit-1 binding sites would generate ‘pituitary-
specific’ activation, and that the upstream exon 1a promoter, which lacks Pit-1 binding sites, would be 
active only in non-pituitary cells [10]. The recombinant BAC approach also allowed us to evaluate 
possible differences in transcriptional timing in relation to promoter structure and transcription factor 
binding.  
Alternative promoters are a common occurrence in the mammalian genome and can allow diversity 
and flexibility in gene expression [45, 46]. The hPRL proximal and distal promoter regions differ 
greatly in their architecture with distinct enhancer and regulatory region configuration (Supplemental 
Figure 1 [38]). A major difference is the presence of multiple Pit-1 binding sites in the proximal 
promoter region. We have shown here that the alternative ‘non-pituitary’ promoter is transcriptionally 
active in pituitary cells, albeit at a greatly reduced level. This suggests that the two hPRL gene 
promoters display tissue preference rather than absolute tissue specificity in activation. This 
phenomenon of tissue preference rather than tissue exclusivity has been reported in a variety of 
human genes [45]. Single-cell analysis of reporter gene expression confirmed that both promoters 
displayed heterogeneous and bursting transcriptional activity, with the alternative promoter associated 
with a significantly reduced transcriptional ‘on’ time and a more binary response. The short ‘on’ 
timing appears to be a specific feature of alternative ‘non-pituitary’ promoter activity as similar 
timing characteristics were observed in primary bone marrow myeloid cells from hPRL-WT 
transgenic rats (Figure 1).  
 
The activity of Pit-1 is regulated in response to signal-transduction pathways by its interaction with 
co-repressor and activator complexes containing nuclear receptor co-repressor 1 (N-CoR) and CREB 
binding protein (CBP) respectively [47]. In response to physiological stimuli Pit-1, through its 
interaction with activator complexes uses the histone acetyltransferase function of CBP [47]. Pit-1 has 
been reported to direct changes in the chromatin structure of the hPRL promoter [48], and changes in 
chromatin structure have been implicated in the timing of hPRL gene transcription [19]. In this work 
we examined the effect of modifications of promoter structure by inactivation of Pit-1 binding sites, 
as well as reduction of transcription factor availability in Pit-1 knockdown experiments. The evidence 
presented here shows that burst timing is affected by the number of transcription factor binding sites 
and transcription factor availability. Binding of transcription factors to regulatory regions can 
influence burst frequency [27] and burst size [42, 49] with differences in function possibly specific to 
certain transcription factors. Previously we have shown that pulsatile patterns of hPRL gene 
expression change during development; nascent primary pituitary lactotroph cells (embryonic day 

















development and in adult pituitary tissue a more stable transcription phenotype is observed [20, 34]. 
Pit-1 mRNA is first detected in the rat anterior pituitary at embryonic day 15 and the protein is 
initially expressed at very low levels [50]. Our data suggest that the difference seen in transcriptional 
bursts during development could be due to the availability of the Pit-1 transcription factor.  
 
An important finding of the present work was that manipulation of the promoter structure had clear 
effects on the timing and structure of transcriptional cycles in living, intact cells. We and others have 
previously found that the prolactin gene, like other genes studied, displays cycles of transcriptional 
activity that are likely to involve chromatin remodelling [19, 23, 37, 51]. The question arises as to 
what elements of promoter structure may control the existence or timing of these cycles. Pit-1 is a 
well-studied transcription factor thought to be necessary for tissue-specific expression of the prolactin 
gene in the pituitary. The prolactin gene proximal promoter contains multiple Pit-1 binding sites that 
are thought to mediate responses to signalling stimuli [4]. Deletion of the Pit-1-regulated promoter 
elements in the human prolactin gene locus did not prevent transcriptional cycles from occurring, but 
did markedly reduce the duration of active periods of transcription, modelled here as ‘on’ periods 
using a stochastic switch model, and also resulted in a less graded, more binary, response profile. This 
suggests that Pit-1 binding in the ‘pituitary-specific’ promoter is important to stabilise transcriptional 
complexes for longer periods to allow higher rates of transcription to occur, and our data are the first 
to indicate that the action of this transcription factor has an important effect on timing.  
 
An important challenge is to assess the physiological significance of pulsatile transcription and the 
role that its modulation may play on normal physiology. The present studies were performed in the 
pituitary GH3 cell line, which has significant limitations: it is an immortalised clonal cell line, and the 
cells lack functional dopamine receptors. Nonetheless, they have proved a valuable test-bed in which 
to explore how pituitary hormones may be regulated, and a system in which complex genetic 
manipulations may be trialled before conducting studies in living animals. In our previous work using 
transgenic hPRL-EGFP reporter rats, we have found identical transcriptional pulses in living intact 
normal pituitary cells [18, 20, 34, 37]. In addition to studying the effects of tissue structure and 
development on dynamic transcriptional patterns, we showed how modification of pulse 
characteristics in individual cells changes the overall mRNA production in a larger population of cells 
(36). Important questions still to be addressed in vivo include studies on the effects of oestrogen and 
dopamine, and also how hormone production by clonal pituitary tumours might differ from that of 
lactotrophs in the intermingled cell populations of the normal pituitary. This work will require further 
use of such animal models, but in the meantime our cell line data indicate that transcriptional timing is 
an important aspect of overall physiological control of pituitary hormone production, and that 
transcription factors such as Pit-1 appear to have a key role in stabilising transcriptional pulses to 


















In summary, Pit1 plays an important role in the timing of transcription cycles, rather than simply 
being necessary to permit tissue-specific gene expression. The proximal promoter displays a binary 
(‘all-or-nothing’) activation step, with the presence of Pit-1 and Pit-1 binding sites associated with 
prolongation of the subsequent ‘on-phase’, and multi-step graded inactivation. In the absence of Pit-1 
or Pit-1 binding, as occurs with the alternative upstream promoter in non-pituitary tissues, both the 
activation and inactivation steps of the transcriptional cycles have binary characteristics of a smaller 
amplitude. Pit-1 is localised in nuclear foci and dynamically partitioned, with a key role in interacting 
with the nuclear matrix [52]. In addition, Pit-1 has been shown to reorganise long range looping [53], 
nuclear co-repressors [54], nucleosome location and  histone acetylation [48]. The current results 
suggest a dynamic rather than passive role for Pit-1 in transcriptional regulation. These results may be 
applicable to the mechanism of action of other master cell-lineage specific transcription factors and to 
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Contrasting cycles of hPRL transcription directed by the alternative and proximal promoters 
Luminescence signal from primary pituitary (a) and bone marrow (BM) myeloid cells (following 
treatment with 0.05% LPS) (b), taken from transgenic rats expressing luciferase under the control of a 
160kb hPRL genomic fragment (hPRL WT BAC). Coloured lines represent data from single cells (c 
n=45 cells; d, n=12 cells) and thick black line represents the population mean. Example single cell 
traces from pituitary cells (e) and BM myeloid cells (f). Luciferase activity from each cell was 
normalised to the average luminescence intensity of all cells in each imaging experiment at time zero.  
 
Figure 2 
Generation of the hPRL PitProKO-Luc BAC 
Schematic illustration of the knock-out of the prolactin proximal pituitary promoter using a 160kb 
hPRL BAC-Luc construct (hPRL WT). 5kb pituitary promoter sequence was replaced with positive 
selection marker Galk, via a seamless BAC recombineering strategy to knock-out the PRL pituitary 
promoter (a). Site-mutations were introduced in the three Pit-1 binding sites present in the proximal 
pituitary promoter (-256/+1) using hPRL 5kbLuc plasmid (b). 256 bp DNA fragment containing 
mutated Pit1 sites along with alternative acceptor site was amplified from hPRL 5kb Luc plasmid 
using BAC homology arms and inserted into the pituitary promoter knock-out BAC replacing the 
Galk gene, thereby creating a construct expressing luciferase under the control of the extra-pituitary 
promoter (PitProKO) (c). GH3 cells containing hPRL WT or hPRL PitProKO BAC constructs were 
fixed in 1% formaldehyde and subjected to ChIP with either non-specific IgG antibody or Pit-1 
specific antibody. DNA was extracted and amplified by primers flanking the first and third pit-1 
binding sites or a non-specific rat GAPDH sequence (d). GalK, galactokinase; Luc, luciferase. 
 
Figure 3 
Schematic of the regulatory elements within the hPRL pituitary and extra-pituitary promoter 
regions. 
Schematic of the hPRL promoter illustrating pituitary and extra-pituitary regions (a). Response 
elements within the pituitary promoter that enable expression of PRL in the pituitary (adapted from 
[4]) (b). Response elements within the extra-pituitary region that enable expression of PRL in extra-
pituitary tissues (including information from [55]) (c). Schematic of the hPRL-Luc 160kb BAC 
expressing luciferase under the control of the entire hPRL gene (d). AP1, activator protein 1; 
cEBPCCAAT binding protein beta; CRE, cAMP response element; ER, estrogen receptor; 
FOXO1A, forkhead box protein O1A; GR, glucocorticoid receptor; HNF-3, hepatocyte nuclear factor 

















TGIF, TG-interacting factor; TRF, TBP (TATA binding protein)-related factor; PR, progesterone 
receptor.  
Figure 4 
Bursting gene transcription of the hPRL alternative promoter 
Single cell transcriptional activity in GH3 hPRL WT and PitProKO cell lines. Representative images 
and single cell transcriptional traces from hPRL WT (4a and c) and hPRL PitProKO cells (4b and d). 
Coloured lines represent data from single cells with the thick black line representing the mean 
response of the population; n=16 (c), n=28 (d). Luciferase activity from three individual hPRL WT 
and three hPRL PitProKO clonal GH3 cell lines (e). Luciferase activity from each cell was normalised 
to the average luminescence intensity of all cells in each imaging experiment at time zero. Estimated 
transcriptional ‘on’ time determined by SSM compared between hPRL WT and PitProKO cells. Bars 
show standard deviation of the cycle length from 56 and 69 cells respectively in three experiments per 
cell type. The duration of an ‘on’ phase is significantly reduced in PitProKO cells (Kolmogorov-
Smirnov, *P < 0.05) (f). 
Figure 5 
Pit-1 binding regulates the timing of hPRL transcription 
Single-cell transcriptional activity of hPRL WT cells following siRNA Pit-1 knockdown or siRNA 
negative control, 72 hours after transfection. Representative images and single-cell transcriptional 
traces from siRNA negative control treated hPRL WT (a and c) and hPRL WT, Pit-1 siRNA 
knockdown cells (b and d). Coloured lines represent data from single cells with the thick black line 
representing the mean response of the population; n=30 cells (c), n=22 cells (d). Luciferase activity 
from each cell was normalised to the average luminescence intensity of all cells in each imaging 
experiment at time zero. Luciferase activity (e) and Pit-1 protein expression ((e) inset) of hPRL WT 
cells following treatment with lipofectamine transfection reagent, siRNA negative control or Pit-1 
siRNA knockdown (KD: knockdown). Estimated transcriptional ‘on’ time determined by SSM, 
compared between hPRL WT scrambled siRNA, and hPRL WT siRNA Pit-1 knockdown. Bars show 
standard deviation of the cycle length from 77 and 62 cells respectively in three experiments per cell 
type. The duration of an ‘on’ phase is significantly reduced in cells with Pit-1 knockdown 
(Kolmogorov-Smirnov, *P < 0.05) (f).  
Figure 6 
Distribution of the switching score S for up and down switching for each of WT, PitProKO, WTPit-1 
knockdown and WT scrambled siRNA. a,d,g,j: the distributions of scores S for up switches for each 
of the four datasets. b,e,h,k: as before (a,d,g,j) but for down switches. c,f,i,l: cumulative distribution 
functions for each of the four datasets. In each case there is a significant difference between the up 
and down switches, with up switches having larger values of S. m: a comparison of the cumulative 


















Author Contribution Statement  
AM performed a majority of the experimental work in the figures, identified key results, and wrote 
the paper. RA designed, constructed and validated the mutant BAC construct that initiated the project, 
and contributed to writing the paper. HM performed the stochastic switch analysis of the single cell 
imaging data. LD performed initial single cell analyses. KF provided bone marrow cells and advised 
on imaging experiments. CH advised throughout the study and assisted with data interpretation. AA 
assisted with BAC recombineering strategy and design. SS made the initial PRL BAC and provided 
training and advice on BAC design. NJ assisted in optimisation Pit-1 knock-down experiments. DS 
contributed to imaging experiments and managed the microscopy equipment. JM advised on the 
project strategy and BAC design. BF led the development and application of the stochastic switch 























































































































/endo/advance-article/doi/10.1210/endocr/bqaa249/6060060 by guest on 01 February 2021
